On January 18, Dr. Opaskarn Kawinpong, MD. Director-General, Department of Disease Control Revealed that now Thailand has made progress on the import of the COVID-19 vaccine. At present, there is one COVID-19 vaccine manufacturer submitting documents to the Food and Drug Administration (FDA) for efficacy and safety checks.
Compare “the COVID-19 vaccine” why Thailand has to reserve “Astra Seneca – Oxford”
Indonesia’s first vaccine “Sinovac”
The COVID-19 “Oxford” vaccine is effective for older adults.
It is believed that this vaccine is safe and effective to an acceptable level after the FDA has reviewed the document. It is according to the plan that the vaccine will be injected to Thai people from February onwards, but initially it is expected that the vaccine will be used as an emergency in Thailand no more than a week
For those who are concerned about side effects The Director-General of the Department of Disease Control said there would be a follow-up system after vaccination to look at the symptoms at least 4 weeks for abnormalities. What are the adverse reactions to the drug? If someone has been harmed or died? There will be a committee to investigate details to see if it is relevant to the vaccination. And will consider whether to continue vaccination or stop vaccination
Dr. Surachok Tangwiwat, Deputy Secretary-General of the Food and Drug Administration (FDA) revealed that AstraZeneca (developed by the University of Oxford) has registered the COVID-19 vaccine. To the FDA this time It is an application for registration from a production lot abroad. At present, the documents have been submitted quite complete, but the FDA has requested the company to send complete additional documents regarding the quality, production standards of foreign factories. The specialist will then determine whether the registration is approved.
When complete documents can be considered within 1 week.
The Deputy Secretary of the FDA clarified that if this Vaccine Astra Seneca In overseas production lots are registered. Will affect the same COVID-19 vaccine that Siam Bioscience Co., Ltd. has inherited the technology To be produced in Thailand 26 million doses. When finished in Thailand, it will make the registration faster. Because there is the same production evidence as a foreign production lot that has been registered by the FDA
However, the private sector could not import the vaccine because AstraZeneca applied for registration, stating that It is an approval for registration in emergencies. Will be sold to the Thai government only
First injection COVID-19 vaccine From oxford That Thailand has reserved 26 million doses
– .
